



○ SKM  
transcription  
factors



For therapeutic PSC,  
one need to assess  
its mutation profile  
and ensure the  
integrity and stability  
of PSC's genome,  
thus ruling out  
traditional retroviral  
delivery

Even a treatment has  
been shown to work in  
animal models, it might  
not translate to successful  
clinic trials for some  
subtle differences in  
underlying biology. For the  
lucky ones with proved  
therapeutic value and  
license issued, they might  
still suffer from  
expensiveness. Take AMD  
treatment as example,  
while the conventional  
strategy costs \$5,000 per  
patient per year, the PSC-  
based strategy costs

A induction efficiency of  
5% might be satisfactory  
for lab usage, but would  
be feasible when 10  
billion cells are required  
to implement a  
treatment or a High-  
throughput screening. .

